Two breakthrough studies in preclinical models demonstrated the effectiveness of PARPi in the treatment of these cancers by showing synthetic lethality between the PARPi and the mutations in BRCA1/2 encoding components of homologous recombination-mediated DNA repair (HRR) pathways [5, 6]. This evidence concerns the gene BRCA1 and cancer.